Hanna, Daire http://orcid.org/0000-0003-2921-7652
Merrick, Sophie
Ghose, Aruni
Devlin, Michael John
Yang, Dorothy D.
Phillips, Edward
Okines, Alicia http://orcid.org/0000-0002-2068-2593
Chopra, Neha
Papadimatraki, Elisavet
Ross, Kirsty
Macpherson, Iain http://orcid.org/0000-0003-4295-8885
Boh, Zhuang Y.
Michie, Caroline O. http://orcid.org/0000-0001-9198-0224
Swampillai, Angela
Gupta, Sunnia
Robinson, Tim
Germain, Lewis
Twelves, Chris http://orcid.org/0000-0002-1849-7153
Atkinson, Charlotte
Konstantis, Apostolos
Riddle, Pippa
Cresti, Nicola
Naik, Jay D.
Borley, Annabel
Guppy, Amy
Schmid, Peter
Phillips, Melissa
Article History
Received: 27 October 2023
Revised: 28 March 2024
Accepted: 5 April 2024
First Online: 24 April 2024
Competing interests
: Dr Daire Hanna: Honorarium from Gilead. Dr Melissa Phillips: Honorarium from Gilead, Esai, Novartis, Roche, Pfizer, MSD. Dr Caroline Michie: Speaker fees or advisory board funding from Gilead, AstraZeneca, Eisai, Eli Lilly, Novartis, Pfizer, Roche, Exact Sciences and Seagen; conference travel support from Novartis and Roche. Dr Tim Robinson: Funding for conference attendance from MSD; funding for educational workshops from Daiichi-Sanko; supported by an NIHR Development and Skills Enhancement Award (NIHR 302363). Dr Iain MacPherson: Consulting fees from Astra Zeneca, Eli Lilly, Gilead, Novartis, Pfizer, Roche, and Stemline Therapeutics. Dr Neha Chopra: conference grant from Gilead; presentation fees from Pfizer. Dr Amy Guppy: conference grant from Gilead; funding for educational workshops from Novartis and Exact Science. Dr Jay Naik: non-promotional educational support (workshops/facilitation) from AstraZeneca and Daiichi. All other authors declare no conflicts of interest.
: The study was performed in accordance with the declaration of Helsinki. The need for ethical approval was waivered as the local ethics board do not consider applications on clinical audits or evaluations of anonymous data from routinely gathered records.